For example, CTLA-4 inhibitors are associated with higher rates of colitis and hypophysitis, whereas PD-(L)1 inhibitors more frequently lead to thyroiditis, pneumonitis, and autoimmune diabetes [13]. Here, CTLA4 is linked to hypophysitis.